## **Tobias Hofving**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7111662/publications.pdf

Version: 2024-02-01

		1478505	1474206	
8	229	6	9	
papers	citations	h-index	g-index	
9	9	9	425	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors. BMC Cancer, 2021, 21, 101.	2.6	7
2	The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. Cancers, 2021, 13, 4305.	3.7	7
3	H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines. Nature Genetics, 2019, 51, 1426-1427.	21.4	4
4	177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocrine-Related Cancer, 2019, 26, 437-449.	3.1	14
5	The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocrine-Related Cancer, 2018, 25, 367-380.	3.1	58
6	NAMPT Inhibitor GMX1778 Enhances the Efficacy of <sup>177</sup> Lu-DOTATATE Treatment of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 288-292.	5.0	33
7	Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets. Modern Pathology, 2016, 29, 616-629.	5.5	36
8	Extreme Female Promiscuity in a Non-Social Invertebrate Species. PLoS ONE, 2010, 5, e9640.	2.5	52